Arcellx News

Gilead to Buy Arcellx in $8B CAR‑T Deal

February 23, 2026

Gilead is set to acquire Arcellx for about $7.8–8B in cash, paying roughly $115 per share and positioning its multiple myeloma CAR‑T against J&J’s Carvykti.